RT Journal Article
SR Electronic
T1 Autoantibodies in COVID-19 correlate with anti-viral humoral responses and distinct immune signatures
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.08.22268901
DO 10.1101/2022.01.08.22268901
A1 Patrick Taeschler
A1 Carlo Cervia
A1 Yves Zurbuchen
A1 Sara Hasler
A1 Christian Pou
A1 Ziyang Tan
A1 Sarah Adamo
A1 Miro E. Raeber
A1 Esther Bächli
A1 Alain Rudiger
A1 Melina Stüssi-Helbling
A1 Lars C. Huber
A1 Petter Brodin
A1 Jakob Nilsson
A1 Elsbeth Probst-Müller
A1 Onur Boyman
YR 2022
UL http://medrxiv.org/content/early/2022/01/10/2022.01.08.22268901.abstract
AB Background Several autoimmune features occur during coronavirus disease 2019 (COVID-19), with possible implications for disease course, immunity, and autoimmune pathology.Objective We longitudinally screened for clinically relevant systemic autoantibodies to assess their prevalence, temporal trajectory, and association with immunity, comorbidities, and severity of COVID-19.Methods We performed highly sensitive indirect immunofluorescence assays to detect anti-nuclear antibodies (ANA) and anti-neutrophil cytoplasmic antibodies (ANCA), along with serum proteomics and virome-wide serological profiling in a multicentric cohort of 175 COVID-19 patients followed-up to one year after infection, eleven vaccinated individuals, and 41 unexposed controls.Results Compared to healthy controls, similar prevalence and patterns of ANA were present in patients during acute COVID-19 and recovery. However, paired analysis revealed a subgroup of patients with transient presence of certain ANA patterns during acute COVID-19. Furthermore, patients with severe COVID-19 exhibited a high prevalence of ANCA during acute disease. These autoantibodies were quantitatively associated with higher SARS-CoV-2-specific antibody titers in COVID-19 patients and in vaccinated individuals, thus linking autoantibody production to increased antigen-specific humoral responses. Notably, the qualitative breadth of antibodies cross-reactive with other coronaviruses was comparable in ANA-positive and ANA-negative individuals during acute COVID-19. In autoantibody-positive patients, multiparametric characterization demonstrated an inflammatory signature during acute COVID-19 and alterations of the B cell compartment after recovery.Conclusion Highly sensitive indirect immunofluorescence assays revealed transient autoantibody production during acute SARS-CoV-2 infection, while the presence of autoantibodies in COVID-19 patients correlated with increased anti-viral humoral immune responses and inflammatory immune signatures.Key messages - Acute COVID-19 patients exhibit transient autoantibody production, indicating a temporary loss of self-tolerance.- In COVID-19 patients, the presence of autoantibodies is associated with increased anti-viral humoral immune responses and inflammatory immune signatures that persist into recovery.Capsule Summary Autoantibodies in COVID-19 patients are transient and correlate with increased anti-viral humoral immune responses and an inflammatory immune signature persisting into recovery.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Swiss National Science Foundation grants 310030-172978 and 310030-200669 (to OB), 4078P0-198431 (to OB and JN) and NRP78 Implementation Programme (to CC and OB), Digitalization Initiative of the Zurich Higher Education Institutions Rapid-Action Call #2021.1_RAC_ID_34 (to CC), Swiss Academy of Medical Sciences grants 323530-191220 (to CC), 323530-191230 (to YZ) and 323530-177975 (to SA), Forschungskredit Candoc of University of Zurich FK-20-022 (to SA), Young Talents in Clinical Research Project Grant (YTCR 08/20) by the Swiss Academy of Medical Sciences and Bangerter Foundation (to MER), the Clinical Research Priority Program of University of Zurich for CRPP CYTIMM-Z (to OB), the Pandemic Fund of University of Zurich (to OB), and an Innovation Grant of University Hospital Zurich (to OB).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Cantonal Ethics Committee of Zurich, Switzerland (BASEC #2016-01440)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors